Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030

被引:886
作者
Bommer, Christian [1 ,2 ]
Sagalova, Vera [1 ,2 ]
Heesemann, Esther [1 ,2 ]
Manne-Goehler, Jennifer [3 ,4 ]
Atun, Rifat [4 ,5 ,6 ]
Baernighausen, Till [4 ,7 ,8 ]
Davies, Justine [9 ,10 ]
Vollmer, Sebastian [1 ,2 ,4 ]
机构
[1] Univ Gottingen, Dept Econ, Gottingen, Germany
[2] Univ Gottingen, Ctr Modern Indian Studies, Gottingen, Germany
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA USA
[4] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA USA
[5] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA
[6] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA USA
[7] Heidelberg Univ, Heidelberg Inst Publ Hlth, Heidelberg, Germany
[8] Africa Hlth Res Inst, Somkhele, South Africa
[9] Kings Coll London, Ctr Global Hlth, London, England
[10] Univ Witwatersrand, Sch Publ Hlth, Wits Rural Publ Hlth & Hlth Transit Res Unit, MRC, Johannesburg, South Africa
关键词
SUSTAINABLE DEVELOPMENT GOALS; HEALTH; CARE; FUTURE; COSTS;
D O I
10.2337/dc17-1962
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
OBJECTIVE Despite the importance of diabetes for global health, the future economic consequences of the disease remain opaque. We forecast the full global costs of diabetes in adults through the year 2030 and predict the economic consequences of diabetes if global targets under the Sustainable Development Goals (SDG) and World Health Organization Global Action Plan for the Prevention and Control of Non communicable Diseases 2013-2020 are met. RESEARCH DESIGN AND METHODS We modeled the absolute and gross domestic product (GDP)-relative economic burden of diabetes in individuals aged 20-79 years using epidemiological and demographic data, as well as recent GDP forecasts for 180 countries. We assumed three scenarios: prevalence and mortality 1) increased only with urbanization and population aging (baseline scenario), 2) increased in line with previous trends (past trends scenario), and 3) achieved global targets (target scenario). RESULTS The absolute global economic burden will increase from U.S. $1.3 trillion (95% CI 1.3-1.4) in 2015 to $2.2 trillion (2.2-2.3) in the baseline, $2.5 trillion (2.4-2.6) in the past trends, and $2.1 trillion (2.1-2.2) in the target scenarios by 2030. This translates to an increase in costs as a share of global GDP from 1.8%(1.7-1.9) in 2015 to amaximumof 2.2%(2.1-2.2). CONCLUSIONS The global costs of diabetes and its consequences are large and will substantially increase by 2030. Even if countries meet international targets, the global economic burden will not decrease. Policy makers need to take urgent action to prepare health and social security systems to mitigate the effects of diabetes.
引用
收藏
页码:963 / 970
页数:8
相关论文
共 33 条
[1]
Is health care a necessary or luxury product for Asian countries? An answer using panel approach [J].
Abdullah, S. M. ;
Siddiqua, Salina ;
Huque, Rumana .
HEALTH ECONOMICS REVIEW, 2017, 7
[2]
[Anonymous], GLOB HLTH EXP DAT
[3]
[Anonymous], 2017, WORLD DEV INDICATORS
[4]
Diabetes in sub-Saharan Africa: from clinical care to health policy [J].
Atun, Rifat ;
Davies, Justine I. ;
Gale, Edwin A. M. ;
Barnighausen, Till ;
Beran, David ;
Kengne, Andre Pascal ;
Levitt, Naomi S. ;
Mangugu, Florence W. ;
Nyirenda, Moffat J. ;
Ogle, Graham D. ;
Ramaiya, Kaushik ;
Sewankambo, Nelson K. ;
Sobngwi, Eugene ;
Tesfaye, Solomon ;
Yudkin, John S. ;
Basu, Sanjay ;
Bommer, Christian ;
Heesemann, Esther ;
Manne-Goehler, Jennifer ;
Postolovska, Iryna ;
Sagalova, Vera ;
Vollmer, Sebastian ;
Abbas, Zulfiqarali G. ;
Ammon, Benjamin ;
Angamo, Mulugeta Terekegn ;
Annamreddi, Akhila ;
Awasthi, Ananya ;
Besancon, Stephane ;
Bhadriraju, Sudhamayi ;
Binagwaho, Agnes ;
Burgess, Philip I. ;
Burton, Matthew J. ;
Chai, Jeanne ;
Chilunga, Felix P. ;
Chipendo, Portia ;
Conn, Anna ;
Joel, Dipesalema R. ;
Eagan, Arielle W. ;
Gishoma, Crispin ;
Ho, Julius ;
Jong, Simcha ;
Kakarmath, Sujay S. ;
Khan, Yasmin ;
Kharel, Ramu ;
Kyle, Michael A. ;
Lee, Seitetz C. ;
Lichtman, Amos ;
Malm, Carl P. ;
Mbaye, Maimouna N. ;
Muhimpundu, Marie A. .
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08) :622-667
[5]
The projected health care burden of Type 2 diabetes in the UK from 2000 to 2060 [J].
Bagust, A ;
Hopkinson, PK ;
Maslove, L ;
Currie, CJ .
DIABETIC MEDICINE, 2002, 19 :1-5
[6]
Baltagi BH, 2010, IZA DISCUSSION PAPER, P4851
[7]
Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140-2147 [J].
Bergenstal, Richard M. ;
Rosenstock, Julio ;
Arakaki, Richard F. ;
Prince, Melvin J. ;
Qu, Yongming ;
Sinha, Vikram P. ;
Howey, Daniel C. ;
Jacober, Scott J. .
DIABETES CARE, 2013, 36 (07) :E107-+
[8]
Bloom DE, 2017, 23601 NAT BUR EC RES
[9]
Bloom LR., 2011, The Global Economic Burden of Noncommunicable Diseases
[10]
The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study [J].
Bommer, Christian ;
Heesemann, Esther ;
Sagalova, Vera ;
Manne-Goehler, Jennifer ;
Atun, Rifat ;
Barnighausen, Till ;
Vollmer, Sebastian .
LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (06) :423-430